A process developed by University of Queensland researchers to produce larger quantities of the Hendra virus therapeutic antibody could be expanded to manufacture treatments for other potentially deadly viruses around the world.
Researchers at UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN)
used this process to produce material for Queensland Health’s world-first human Hendra virus clinical trial.
Comments